7 Red Flags to Watch For When Sourcing Exosomes & Stem Cells: A Buyer's Guide for Licensed Practitioners
The exosome and mesenchymal stem cell market has expanded faster than the regulatory framework around it. Practitioners evaluating suppliers face a flood of marketing claims with no easy way to separate credentials that mean something from credentials that are inflated, misused, or fabricated entirely.
This is a problem with real consequences. A single sourcing decision exposes the practice to product liability, professional licensure risk, and the very real possibility of administering a biologic that was not what the label claimed.
This article gives licensed practitioners seven specific red flags to evaluate any prospective biologics supplier — and the right questions to ask in their place. It is written for MDs, DOs, NPs, PAs, and practice administrators sourcing biologics for the first time, switching suppliers, or auditing an existing relationship.
Key takeaway: The biologics supply industry has legitimate quality signals — AATB accreditation, FDA tissue establishment registration, cGTP compliance under 21 CFR Part 1271, NTA-verified particle counts, and dual-lab Certificates of Analysis. Anything outside that framework, especially "FDA-approved" exosomes or "cGMP" stem cells, is a sign the supplier is either uninformed about the regulatory framework or willing to misrepresent it.
1"FDA-Approved" Exosome or Stem Cell Products
This is the single most common — and most disqualifying — claim in the market. There are currently no FDA-approved exosome products in the United States. None. Any supplier marketing exosomes as "FDA-approved" is making a claim that is factually incorrect.
The same applies to umbilical cord tissue-derived mesenchymal stem cells (UCT-MSCs). MSCs are regulated under 21 CFR Part 1271 as human cells, tissues, and cellular and tissue-based products (HCT/Ps), not as approved drugs.
Suppliers who confuse FDA registration (a facility credential) with FDA approval (a product license) are either misinformed or counting on the practitioner being misinformed. Either way, the supplier is creating regulatory exposure that lands on the prescriber, not the supplier.
2Misuse of "cGMP" for Tissue-Based Products
cGMP and cGTP are not interchangeable terms. They reference two distinct regulatory frameworks:
| Standard | Regulation | Applies To |
|---|---|---|
| cGMP — Current Good Manufacturing Practice | 21 CFR Parts 210 / 211 | Drug products approved by the FDA |
| cGTP — Current Good Tissue Practice | 21 CFR Part 1271 | Human cell and tissue-based products (HCT/Ps), including UCT-MSCs and exosomes |
A supplier marketing UCT-MSC vials or exosome biologics as "cGMP-manufactured" is conflating two different regulatory categories. The correct framework for these products is cGTP under 21 CFR Part 1271. Florida's HB 1768 explicitly references cGMP for stem cell products in certain contexts, and FDA materials distinguish between the two — but the loose, marketing-driven use of "cGMP" for HCT/Ps is a credibility flag.
This isn't pedantry. A supplier who can't get their own regulatory category right is also unlikely to have downstream documentation, donor screening, and chain-of-custody systems built correctly.
3Single-Lab COAs With No Independent Verification
A Certificate of Analysis from the manufacturer's own internal lab is not independent verification. The manufacturer producing the product is the same entity testing the product — a structural conflict of interest, regardless of how rigorous the internal lab actually is.
The credibility standard is dual-lab testing: the manufacturer runs internal QC, and an independent third-party lab runs verification testing on the same lot. Both results appear on the COA, and any discrepancy between them is documented and explained.
If a supplier can only produce a single-lab COA on their own letterhead, the practitioner is being asked to trust a self-graded report card.
4Particle Counts Without NTA Verification
Marketing claims like "60 billion exosomes per vial" or "150 billion particles" are meaningless without the measurement method. Nanoparticle Tracking Analysis (NTA) is the recognized industry standard for quantifying extracellular vesicle concentration and size distribution. Other methods — dynamic light scattering (DLS), nanoflow cytometry, theoretical yield calculations — measure different things and are not interchangeable with NTA.
Without NTA documentation on the COA, particle counts can be:
- Inflated — counted using methods that include cellular debris, protein aggregates, and non-vesicle particles
- Estimated — calculated from input cell counts rather than measured in the final product
- Theoretical — pulled from manufacturing process averages rather than tested per-lot
A supplier unwilling or unable to provide NTA-verified, lot-specific particle counts is selling a number, not a product specification.
5Vague or Missing Source Tissue Documentation
Not all umbilical cord tissue is equivalent. The variables that matter — and that legitimate suppliers document — include:
- Tissue source — Wharton's Jelly from human umbilical cord, ethically donated after live full-term birth
- Donor screening — HIV-1/2, hepatitis B and C, HTLV-I/II, syphilis, West Nile, CMV, and other infectious disease panels per FDA donor eligibility requirements (21 CFR Part 1271 Subpart C)
- Pregnancy generation — first-pregnancy donors yield younger, less senescent cells
- Country of origin — domestic U.S. sourcing under FDA jurisdiction vs. imported tissue from jurisdictions with different oversight
- Population doublings (PD) — lower PD counts indicate biologically younger cells with less replication-aged DNA damage and oxidative stress burden
A supplier who can't or won't disclose these variables is selling tissue with an unknown provenance. That's a chain-of-custody failure that becomes the practitioner's problem the moment it's administered.
6Mechanism-of-Action and Disease Claims in Marketing
This is the regulatory framework most commonly violated by exosome and stem cell suppliers. Under FDA's framework, mechanism-of-action claims function as therapeutic claims — and therapeutic claims convert a non-drug biologic into an unapproved drug.
Claims that cross this line include:
- "Anti-inflammatory" or "modulates inflammation"
- "Immune modulating" or "regulates the immune system"
- "Stem cell activating" or "amplifies stem cell function"
- "Tissue regenerating" or "rebuilds tissue"
- "Angiogenic" or "promotes new blood vessel formation"
- "Treats," "cures," "heals," or any disease-named indication
Why this matters for the practitioner: A supplier publishing mechanism or disease claims is documenting their own regulatory exposure. If FDA action follows, those claims appear in enforcement records — and any practitioner who relied on that marketing as the basis for clinical use is implicated by association. Compliant suppliers position exosomes as topical cosmetic biologics for licensed professional use only, with no disease or mechanism claims.
7No AATB Accreditation or FDA Tissue Establishment Registration
AATB (American Association of Tissue Banks) accreditation and FDA tissue establishment registration are the two foundational regulatory credentials for HCT/P suppliers in the United States. They are not optional.
Florida's HB 1768 specifically names the American Association of Tissue Banks as one acceptable accrediting body for stem cell products. Other states with stem cell legislation reference similar accreditation standards. A supplier without AATB accreditation is operating outside the recognized regulatory framework that state legislatures explicitly point to.
FDA tissue establishment registration is a separate but related credential. Any facility that recovers, processes, stores, labels, packages, or distributes HCT/Ps is required to register with the FDA under 21 CFR Part 1271. The registration is searchable in FDA's public database. A supplier who can't produce their FDA establishment registration number is either unregistered or unwilling to disclose — both of which are disqualifying.
The Buyer's Evaluation Checklist
Use this checklist when evaluating any prospective biologics supplier
If a supplier can't produce documentation for any item on this list, that's a sourcing decision worth escalating. If they can't produce documentation for three or more, that's a supplier worth replacing.
Source biologics with complete regulatory documentation.
Stem Nova Network is an FDA-Registered Tissue Establishment, AATB-accredited, cGTP-compliant under 21 CFR Part 1271. Every lot ships with a dual-lab COA, NTA-verified particle counts, and full donor screening documentation.
Enroll Your Practice Contact Our Team